# A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

> **NCT00421304** · NA · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 118 (actual)

## Conditions studied

- RSV Illness in ≤12 Months of Participants

## Interventions

- **BIOLOGICAL:** Motavizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00421304
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-10
- **Primary completion:** 2009-09-17
- **Final completion:** 2009-09-17
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421304, "A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00421304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*